BioCentury
ARTICLE | Clinical News

Diffusion to start Phase III GBM trial of TSC

November 10, 2017 9:31 PM UTC

By year end, Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) will begin a Phase III trial to compare trans sodium crocetinate (TSC) plus standard of care (SOC), including chemotherapy and radiation, vs. SOC alone to treat newly diagnosed, inoperable glioblastoma multiforme (GBM)...

BCIQ Company Profiles

Diffusion Pharmaceuticals Inc.